THURSDAY, Sept. 26 (HealthDay News) -- Doctors might be able to
overcome antibiotic-resistant bacteria by swapping out the
antibiotics used to treat a patient, providing a "one-two" punch
that keeps the germs reeling, a new Danish study suggests.
The strategy relies on a concept called "collateral
sensitivity," in which bacteria that become resistant to one
antibiotic also become more vulnerable to other antibiotics.
The researchers argue that by swapping between antibiotics that
play well off each other, doctors can stay one step ahead of
bacteria and continuously avoid resistance.
"You cycle between drugs that have reciprocal sensitivities," explained study co-author Morten Sommer, a lead researcher with the Novo Nordisk Foundation Center for Biosustainability at the Technical University of Denmark.
"If you become resistant to drug A, you will become more sensitive to drug B. That way, you can cycle between drug A and drug B without increasing resistance in the long term," he added.
The U.S. Centers for Disease Control and Prevention recently
declared antibiotic-resistant bacteria one of America's most
serious health threats, estimating that more than 2 million people
are sickened and at least 23,000 die every year due to
antibiotic-resistant infections. Doctors are finding it
increasingly hard to fight some infections because many antibiotics
have become useless against bacteria that have developed resistance
to the drugs.
The new study was published Sept. 25 in the journal
Science Translational Medicine.
The concept of collateral sensitivity has been around since the
1950s, but never received much attention, Sommer said.
"I think basically it was discovered during the golden age of antibiotic development," he said. "There were new drugs coming onto the market all the time, and there wasn't the need that there is today for a strategy to counter resistance."
To test the concept, Sommer and his research team exposed E.
coli bacteria to 23 different commonly used antibiotics, allowing
the germs to develop resistance. Then they tested how each of the
now-resistant bacteria responded to other antibiotics.
The researchers found that most antibiotics on the market can be
"paired" with another antibiotic. As resistance to the first drug
increases, the bacteria become more vulnerable to the other drug.
In other cases, antibiotics can be used in a sequential deployment
of three or four different drugs.
As many as 200 already approved antibiotics could be used in
this manner, with one medication playing off one or more others,
"The timing will depend on the resistance development that's occurring in the patient," he said. "A doctor will want to cycle the drug when patient improvement slows or stops."
This cycling strategy could be most helpful for patients
suffering from long-term infectious diseases like tuberculosis or
cystic fibrosis, Sommer suggested. "We think this treatment
strategy will be primarily relevant when the patient is suffering a
chronic infection," he said. "In those cases, the infection
continues for a long time, which allows for resistance to
Collateral sensitivity cycling also could help increase the life
span of many antibiotics, allowing them to remain useful tools for
longer periods, the study authors added.
The researchers said their findings need further testing in
animals and then in patient clinics.
This strategy likens bacteria to science fiction villains that
automatically adapt to any weapon used against them, said Victoria
Richards, associate professor of medical sciences at Quinnipiac
University's Frank H. Netter MD School of Medicine, in North Haven,
"Any antibiotic is a weapon against a bacteria," she said. "With this approach, they could break that cycle of bacteria trying to adapt to our weapons."
Richards said doctors and hospitals might want to consider
implementing this sort of cycling strategy as soon as possible, as
part of their overall plan to prevent resistance.
"It's not like these are experimental antibiotics," she said. "They are commonly used, and can be used in response to the bacteria responding to other antibiotics. It's trying to keep one step ahead of the bacteria, by looking in a different way at antibiotics that have been used for decades."
For more on antibiotic resistance, visit the
U.S. Centers for Disease Control and
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.